🇺🇸 FDA
Patent

US 6579893

Use of troglitazone and related compounds for the treatment of cancer

expired A61KA61K31/426A61K31/427

Quick answer

US patent 6579893 (Use of troglitazone and related compounds for the treatment of cancer) held by The Board of Regents of the University of Texas System expires Mon Jun 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jun 17 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/426, A61K31/427, A61K31/4439, A61P